Deutsche Bank Analysts Give Fresenius Medical Care AG & Co. KGAA (FME) a €83.00 Price Target

Fresenius Medical Care AG & Co. KGAA (ETR:FME) received a €83.00 ($98.81) target price from equities research analysts at Deutsche Bank in a research report issued to clients and investors on Friday. The firm presently has a “neutral” rating on the stock. Deutsche Bank’s target price indicates a potential upside of 0.40% from the stock’s previous close.

FME has been the subject of a number of other reports. S&P Global set a €95.00 ($113.10) price objective on shares of Fresenius Medical Care AG & Co. KGAA and gave the stock a “buy” rating in a research note on Monday, November 6th. Credit Suisse Group set a €92.00 ($109.52) price objective on shares of Fresenius Medical Care AG & Co. KGAA and gave the stock a “buy” rating in a research report on Monday, November 6th. HSBC set a €85.00 ($101.19) price objective on shares of Fresenius Medical Care AG & Co. KGAA and gave the company a “neutral” rating in a research note on Wednesday, November 22nd. Goldman Sachs Group set a €97.00 ($115.48) price target on shares of Fresenius Medical Care AG & Co. KGAA and gave the stock a “buy” rating in a report on Monday, November 6th. Finally, Independent Research set a €88.00 ($104.76) target price on shares of Fresenius Medical Care AG & Co. KGAA and gave the stock a “neutral” rating in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of €89.05 ($106.02).

Fresenius Medical Care AG & Co. KGAA (ETR:FME) opened at €82.67 ($98.42) on Friday. Fresenius Medical Care AG & Co. KGAA has a fifty-two week low of €71.49 ($85.11) and a fifty-two week high of €89.22 ($106.21).

TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/01/deutsche-bank-analysts-give-fresenius-medical-care-ag-83-00-price-target.html.

Fresenius Medical Care AG & Co. KGAA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. KGAA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGAA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGAA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply